Davis R M Inc Gilead Sciences, Inc. Transaction History

Davis R M Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 10, 2021	SELL	$60.0 - $68.46 $223,260 - $254,739	-3,721 Closed	0 $0
Q4 2020 Jan 27, 2021	BUY	$56.65 - $64.55 $22,150 - $25,239	391 Added 11.74%	3,721 $217,000
Q3 2020 Dec 01, 2020	SELL	$62.1 - $78.08 $18,630 - $23,424	-300 Reduced 8.26%	3,330 $210,000
Q2 2020 Jul 20, 2020	BUY	$72.34 - $84.0 $43,259 - $50,232	598 Added 19.72%	3,630 $279,000
Q1 2020 Apr 24, 2020	SELL	$62.63 - $80.22 $125,260 - $160,440	-2,000 Reduced 39.75%	3,032 $227,000
Q4 2019 Jan 23, 2020	BUY	$61.62 - $67.78 $22,799 - $25,078	370 Added 7.94%	5,032 $327,000
Q3 2019 Oct 24, 2019	BUY	$62.51 - $69.0 $291,421 - $321,678	4,662 New	4,662 $295,000
Q2 2018 Jul 19, 2018	SELL	$64.88 - $75.68 $633,034 - $738,409	-9,757 Closed	0 $0
Q1 2018 Apr 19, 2018	SELL	$72.84 - $88.8 $208,759 - $254,500	-2,866 Reduced 22.7%	9,757 $736,000
Q4 2017 Jan 16, 2018	SELL	$71.15 - $83.52 $414,946 - $487,088	-5,832 Reduced 31.6%	12,623 $904,000
Q3 2017 Oct 24, 2017	BUY	$72.11 - $85.47 $1.33 Million - $1.58 Million	18,455	18,455 $1.5 Million

1,926

992M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $118B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Davis R M Inc, based on Form 13F filings with the SEC.

Stay updated on Davis R M Inc with notifications on news.